We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
+$33.5M
Cap. Flow
+$27.2M
Cap. Flow %
11.87%
Top 10 Hldgs %
55.53%
Holding
52
New
16
Increased
8
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.17M
2
IPXL
Impax Laboratories, Inc.
IPXL
+$8.28M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.71M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$6.21M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$4.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.5M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.02M
3
CELG
Celgene Corp
CELG
+$2.56M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$2.21M
5
TVRD
Tvardi Therapeutics
TVRD
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 70.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
26
CALL
Tvardi Therapeutics
TVRD
$23.5M
$2.24M 0.98%
4,044
+1,961
+94% +$1.24M
RARX
27
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.91M 0.83%
+102,054
New +$2.3M
KMDA icon
28
Kamada
KMDA
$407M
$1.8M 0.79%
+300,781
New +$2.14M
KDNY
29
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.77M 0.77%
+31,000
New +$1.56M
ADXS
30
DELISTED
Advaxis Inc
ADXS
$1.64M 0.71%
16,800
+10,347
+160% +$1.21M
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$1.3M 0.57%
+9,300
New +$1.35M
NGNE icon
32
Neurogene
NGNE
$696M
$1.28M 0.56%
+4,535
New +$1.3M
RNTX
33
Rein Therapeutics
RNTX
$67.7M
$1.27M 0.55%
+5,705
New +$1.25M
PRTK
34
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.21M 0.53%
50,000
-100,000
-67% -$2.21M
MRNS
35
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$685K 0.3%
125,000
-75,000
-38% -$405K
ZSAN
36
DELISTED
Zosano Pharma Corporation
ZSAN
$590K 0.26%
598
-116
-16% -$120K
SBBP
37
DELISTED
Strongbridge Biopharma plc.
SBBP
$477K 0.21%
+66,756
New +$309K
SRRA
38
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$468K 0.2%
10,000
– –
OVID icon
39
Ovid Therapeutics
OVID
$435M
$320K 0.14%
+30,543
New +$399K
OBSV
40
DELISTED
ObsEva SA Ordinary Shares
OBSV
$299K 0.13%
35,000
-15,000
-30% -$111K
VTGN icon
41
VistaGen Therapeutics
VTGN
$9.29M
$258K 0.11%
4,604
– –
ALKS icon
42
Alkermes
ALKS
$8.82B
– –
-9,400
Closed -$550K
AXSM icon
43
Axsome Therapeutics
AXSM
$12.4B
– –
-400,000
Closed -$1.56M
CLSD
44
DELISTED
Clearside Biomedical
CLSD
– –
-8,051
Closed -$959K
VRTX icon
45
CALL
Vertex Pharmaceuticals
VRTX
$121B
– –
-100,000
Closed -$10.9M
VSTM icon
46
Verastem
VSTM
$532M
– –
-28,000
Closed -$696K
TVRD
47
Tvardi Therapeutics
TVRD
$23.5M
– –
-3,333
Closed -$2.11M
LUMO
48
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-22,222
Closed -$4.82M
NTBL
49
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-952
Closed -$183K
EIGR
50
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-8,787
Closed -$3.02M
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Nexthera Capital held 52 positions worth $230M, up 17% from $196M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Nexthera Capital deployed $27.2M of net new capital in Q2 2017, opening 16 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 100,800 shares worth $9.15M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier.

On the sell side, the largest reduction was Pfizer, an estimated $14.5M trimmed.

  • Nexthera Capital's largest Q2 2017 buy was BioMarin Pharmaceuticals: 100,800 shares worth $9.15M.
  • Nexthera Capital added most to Aclaris Therapeutics in Q2 2017, an estimated $6.21M increase.
  • Nexthera Capital's biggest Q2 2017 reduction was Pfizer, cutting an estimated $14.5M.
  • Nexthera Capital fully exited Eiger BioPharmaceuticals, Inc. in Q2 2017, selling an estimated $3.02M.
  • Nexthera Capital's ten largest holdings make up 56% of its $230M portfolio in Q2 2017.
  • Nexthera Capital opened 16 new positions and closed 11 in Q2 2017.
  • Nexthera Capital's portfolio value rose 17% quarter-over-quarter to $230M.

Based on Nexthera Capital's 13F filing for Q2 2017, filed 14 Aug 2017.